Prognostic significance of the Gustave Roussy immune (GRIm) score in cancer patients: a meta-analysis

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):1–8. doi: 10.3322/caac.21660.
   Web of Science ®Google Scholar
• Liu R, Zhao K, Wang K, et al. Prognostic value of nectin-4 in human cancers: a meta-analysis. Front Oncol. 2023;13:1081655. doi: 10.3389/fonc.2023.1081655.
   PubMedGoogle Scholar
• Bando E, Ji X, Kattan MW, et al. Development and validation of a pretreatment nomogram to predict overall survival in gastric cancer. Cancer Med. 2020;9(16):5708–5718. doi: 10.1002/cam4.3225.
   PubMed Web of Science ®Google Scholar
• Ma L, Chen G, Wang D, et al. A nomogram to predict survival probability of gastric cancer patients undergoing radical surgery and adjuvant chemotherapy. Front Oncol. 2022;12:893998. doi: 10.3389/fonc.2022.893998.
   PubMed Web of Science ®Google Scholar
• Mantzorou M, Koutelidakis A, Theocharis S, et al. Clinical value of nutritional status in cancer: what is its impact and how it affects disease progression and prognosis? Nutr Cancer. 2017;69(8):1151–1176. doi: 10.1080/01635581.2017.1367947.
   PubMed Web of Science ®Google Scholar
• Zhao X, Zhou Y, Liu B, et al. Preoperative neutrophil-lymphocyte ratio (NLR)-binding fibrinogen-albumin ratio (FAR) is superior to platelet-lymphocyte ratio (PLR)-binding fibrinogen-albumin ratio (FAR) and lymphocyte-monocyte (LMR)-binding fibrinogen-albumin ratio (FAR) as predictors of survival in surgical patients with colorectal adenocarcinoma. Med Sci Monit. 2023;29:e939442. doi: 10.12659/MSM.939442.
   PubMed Web of Science ®Google Scholar
• Dai M, Sun Q. Prognostic and clinicopathological significance of prognostic nutritional index (PNI) in patients with oral cancer: a meta-analysis. Aging. 2023;15(5):1615–1627. doi: 10.18632/aging.204576.
   PubMedGoogle Scholar
• Wang Y, Ni Q. Prognostic and clinicopathological significance of systemic immune-inflammation index in cancer patients receiving immune checkpoint inhibitors: a meta-analysis. Ann Med. 2023;55(1):808–819. doi: 10.1080/07853890.2023.2181983.
   PubMed Web of Science ®Google Scholar
• Bigot F, Castanon E, Baldini C, et al. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: the Gustave Roussy immune score (GRIm-Score). Eur J Cancer. 2017;84:212–218. doi: 10.1016/j.ejca.2017.07.027.
   PubMed Web of Science ®Google Scholar
• Minami S, Ihara S, Ikuta S, et al. Gustave Roussy immune score and royal marsden hospital prognostic score are biomarkers of immune-checkpoint inhibitor for non-small cell lung cancer. World J Oncol. 2019;10(2):90–100. doi: 10.14740/wjon1193.
   PubMedGoogle Scholar
• Feng JF, Wang L, Yang X, et al. Gustave Roussy immune score (GRIm-score) is a prognostic marker in patients with resectable esophageal squamous cell carcinoma. J Cancer. 2020;11(6):1334–1340. doi: 10.7150/jca.37898.
   PubMed Web of Science ®Google Scholar
• Lin Y, Liu Z, Qiu Y, et al. Clinical significance of plasma D-dimer and fibrinogen in digestive cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2018;44(10):1494–1503. doi: 10.1016/j.ejso.2018.07.052.
   PubMed Web of Science ®Google Scholar
• Pang HY, Yan MH, Chen LH, et al. Detection of asymptomatic recurrence following curative surgery improves survival in patients with gastric cancer: a systematic review and meta-analysis. Front Oncol. 2022;12:1011683. doi: 10.3389/fonc.2022.1011683.
   PubMed Web of Science ®Google Scholar
• Yang XC, Liu H, Liu DC, et al. Prognostic value of pan-immune-inflammation value in colorectal cancer patients: a systematic review and meta-analysis. Front Oncol. 2022;12:1036890. doi: 10.3389/fonc.2022.1036890.
   PubMedGoogle Scholar
• Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. doi: 10.1186/1745-6215-8-16.
   PubMed Web of Science ®Google Scholar
• Al Darazi G, Martin E, Delord JP, et al. Improving patient selection for immuno-oncology phase 1 trials: external validation of six prognostic scores in a french cancer center. Int J Cancer. 2020;148(10):2502–2511. doi: 10.1002/ijc.33409.
   PubMed Web of Science ®Google Scholar
• Basoglu T, Babacan NA, Ozturk FE, et al. Prognostic value of Gustave Roussy immune score in operable pancreatic adenocarcinoma. Indian J Cancer. 2022;60(2):179–184. doi: 10.4103/ijc.IJC_1049_20.
   Web of Science ®Google Scholar
• Kitadai R, Okuma Y, Hakozaki T, et al. The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases. J Cancer Res Clin Oncol. 2020;146(3):777–785. doi: 10.1007/s00432-019-03104-w.
   PubMed Web of Science ®Google Scholar
• Lenci E, Cantini L, Pecci F, et al. The Gustave Roussy immune (GRIm)-score variation is an early-on-treatment biomarker of outcome in advanced non-small cell lung cancer (NSCLC) patients treated with first-line pembrolizumab. J Clin Med. 2021:10(5):1005.
   PubMed Web of Science ®Google Scholar
• Li SJ, Zhao L, Wang HY, et al. Gustave Roussy immune score based on a three-category risk assessment scale serves as a novel and effective prognostic indicator for surgically resectable early-stage non-small-cell lung cancer: a propensity score matching retrospective cohort study. Int J Surg. 2020;84:25–40. doi: 10.1016/j.ijsu.2020.10.015.
   PubMed Web of Science ®Google Scholar
• Li Y, Pan Y, Lin X, et al. Development and validation of a prognostic score for hepatocellular carcinoma patients in immune checkpoint inhibitors therapies: the hepatocellular carcinoma modified Gustave Roussy immune score. Front Pharmacol. 2021;12:819985. doi: 10.3389/fphar.2021.819985.
   PubMed Web of Science ®Google Scholar
• Ma LX, Espin-Garcia O, Bach Y, et al. Comparison of four clinical prognostic scores in patients with advanced gastric and esophageal cancer. Oncologist. 2023;28(3):214–219. doi: 10.1093/oncolo/oyac235.
   PubMedGoogle Scholar
• Ma LX, Wang Y, Espin-Garcia O, et al. Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma. Br J Cancer. 2023;128(10):1916–1921. doi: 10.1038/s41416-023-02214-0.
   PubMed Web of Science ®Google Scholar
• Minami S, Ihara S, Komuta K. Gustave Roussy immune score is a prognostic factor for chemotherapy-naive pulmonary adenocarcinoma with wild-type epidermal growth factor receptor. World J Oncol. 2019;10(1):55–61. doi: 10.14740/wjon1184.
   PubMedGoogle Scholar
• Minami S, Ihara S, Komuta K. Gustave Roussy immune score and royal marsden hospital prognostic score are prognostic markers for extensive disease of small cell lung cancer. World J Oncol. 2020;11(3):98–105. doi: 10.14740/wjon1275.
   PubMedGoogle Scholar
• Minichsdorfer C, Gleiss A, Aretin MB, et al. Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy. Ann Med. 2022;54(1):1339–1349. doi: 10.1080/07853890.2022.2070660.
   PubMed Web of Science ®Google Scholar
• Nakazawa N, Sohda M, Ubukata Y, et al. Changes in the Gustave Roussy immune score as a powerful prognostic marker of the therapeutic sensitivity of nivolumab in advanced gastric cancer: a multicenter, retrospective study. Ann Surg Oncol. 2022;29(12):7400–7406. doi: 10.1245/s10434-022-12226-4.
   PubMed Web of Science ®Google Scholar
• Tian S, Cao Y, Duan Y, et al. Gustave Roussy immune score as a novel prognostic scoring system for colorectal cancer patients: a propensity score matching analysis. Front Oncol. 2021;11:737283. doi: 10.3389/fonc.2021.737283.
   PubMedGoogle Scholar
• Zhu J, Wang D, Liu C, et al. Development and validation of a new prognostic immune-inflammatory-nutritional score for predicting outcomes after curative resection for intrahepatic cholangiocarcinoma: a multicenter study. Front Immunol. 2023;14:1165510. doi: 10.3389/fimmu.2023.1165510.
   PubMed Web of Science ®Google Scholar
• Pang H, Zhang W, Liang X, et al. Prognostic score system using preoperative inflammatory, nutritional and tumor markers to predict prognosis for gastric cancer: a two-center cohort study. Adv Ther. 2021;38(9):4917–4934. doi: 10.1007/s12325-021-01870-z.
   PubMed Web of Science ®Google Scholar
• Atasever Akkas E, Erdis E, Yucel B. Prognostic value of the systemic immune-inflammation index, systemic inflammation response index, and prognostic nutritional index in head and neck cancer. Eur Arch Otorhinolaryngol. 2023;280(8):3831–3833. doi: 10.1007/s00405-023-08053-2.
   PubMed Web of Science ®Google Scholar
• Pelizzari G, Basile D, Zago S, et al. Lactate dehydrogenase (LDH) response to First-Line treatment predicts survival in metastatic breast cancer: first clues for a Cost-Effective and dynamic biomarker. Cancers. 2019;11(9):1243. doi: 10.3390/cancers11091243.
   Google Scholar
• Ding J, Karp JE, Emadi A. Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: interplay between hematologic and solid neoplastic clones and their microenvironments. Cancer Biomark. 2017;19(4):353–363. doi: 10.3233/CBM-160336.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Cabiddu M, Coinu A, et al. Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. Acta Oncol. 2015;54(7):961–970. doi: 10.3109/0284186X.2015.1043026.
   PubMed Web of Science ®Google Scholar
• Cupp MA, Cariolou M, Tzoulaki I, et al. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med. 2020;18(1):360. doi: 10.1186/s12916-020-01817-1.
   PubMed Web of Science ®Google Scholar
• Li Y, Xu T, Wang X, et al. The prognostic utility of preoperative neutrophil-to-lymphocyte ratio (NLR) in patients with colorectal liver metastasis: a systematic review and meta-analysis. Cancer Cell Int. 2023;23(1):39. doi: 10.1186/s12935-023-02876-z.
   PubMed Web of Science ®Google Scholar
• Melssen MM, Sheybani ND, Leick KM, et al. Barriers to immune cell infiltration in tumors. J Immunother Cancer. 2023;11(4):e006401. doi: 10.1136/jitc-2022-006401.
   PubMedGoogle Scholar
• Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 2010;9:69. doi: 10.1186/1475-2891-9-69.
   PubMed Web of Science ®Google Scholar
• Navaei-Alipour N, Mastali M, Ferns GA, et al. The effects of honey on pro- and anti-inflammatory cytokines: a narrative review. Phytother Res. 2021;35(7):3690–3701. doi: 10.1002/ptr.7066.
   PubMed Web of Science ®Google Scholar